Exscientia Holdings Limited (EXAI): Price and Financial Metrics

Exscientia Holdings Limited (EXAI): $4.38

0.06 (+1.39%)

POWR Rating

Component Grades








Add EXAI to Watchlist
Sign Up

Industry: Biotech




#355 of 363

in industry

EXAI Price/Volume Stats

Current price $4.38 52-week high $9.12
Prev. close $4.32 52-week low $4.17
Day low $4.27 Volume 226,688
Day high $4.49 Avg. volume 717,687
50-day MA $5.86 Dividend yield N/A
200-day MA $6.02 Market Cap 529.49M

EXAI Stock Price Chart Interactive Chart >

Exscientia Holdings Limited (EXAI) Company Bio

Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. It offers end-to-end solution of artificial intelligence and technologies for target identification, drug candidate design, translational models, and patient selection. Its platform allows to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.

EXAI Latest News Stream

Event/Time News Detail
Loading, please wait...

EXAI Latest Social Stream

Loading social stream, please wait...

View Full EXAI Social Stream

Latest EXAI News From Around the Web

Below are the latest news stories about EXSCIENTIA PLC that investors may wish to consider to help them evaluate EXAI as an investment opportunity.

Wall Street Analysts See a 67.76% Upside in Exscientia PLC Sponsored ADR (EXAI): Can the Stock Really Move This High?

The consensus price target hints at a 67.8% upside potential for Exscientia PLC Sponsored ADR (EXAI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Yahoo | December 21, 2023

Exscientia Announces Expansion of its Current Collaboration with Sanofi to Include Existing Exscientia Programme

OXFORD, England, December 21, 2023--Exscientia plc (Nasdaq: EXAI) today announced that Sanofi is adding a new discovery stage programme identified and initially advanced by Exscientia into the current collaboration. In this programme, Exscientia has designed a novel lead series with a potential best in class profile, with preliminary data showing good potency and selectivity towards the target and differentiated molecular properties.

Yahoo | December 21, 2023

Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?

Here is how DexCom (DXCM) and Exscientia PLC Sponsored ADR (EXAI) have performed compared to their sector so far this year.

Yahoo | December 14, 2023

Looking for the Next Big Thing? Add This AI Biotech to Your Watch List Right Now

Exscientia (NASDAQ: EXAI) is one such business undertaking this effort, and it's worth adding to your watch list today. Much like the other biotech businesses hoping to use AI for drug development, Exscientia believes that its AI-based platform can shorten development timelines, reduce failure rates in pre-clinical and clinical trials, and lower costs for drug makers. Exscientia's flagship program is cancer treatment candidate GTAEXS617.

Yahoo | December 7, 2023

Micro/Small Cap Companies Using AI In Drug Discovery Up 35% In November

The AI method is up to 250 times more efficient than the traditional method of drug discovery. reducing timelines for drug discovery, increasing accuracy of efficacy and safety predictions.

TalkMarkets.com | December 6, 2023

Read More 'EXAI' Stories Here

EXAI Price Returns

1-mo -29.70%
3-mo -24.55%
6-mo -13.27%
1-year -22.34%
3-year N/A
5-year N/A
YTD -31.67%
2023 20.26%
2022 -73.03%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!